Towa Pharmaceutical decided at its Board of Directors meeting on June 24, 2026, to dispose of 1,188 shares of treasury stock in accordance with its director compensation system, with the disposal scheduled for July 10. The purpose is to enhance corporate value and motivate management, with the restriction period for transfer of the disposed shares set at 30 years.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4553-20260624-02.pdf","jir_short_summary":"Towa Pharmaceutical decided at its Board of Directors meeting on June 24, 2026, to dispose of 1,188 shares of treasury stock in accordance with its director compensation system, with the disposal scheduled for July 10. The purpose is to enhance corporate value and motivate management, with the restriction period for transfer of the disposed shares set at 30 years.","jir_summary":"### Overview of the disposal\nTowa Pharmaceutical has decided to dispose of 1,188 shares of treasury stock as part of its restricted stock compensation system based on its director compensation\u5236\u5ea6. The disposal date is scheduled for July 10, 2026, with a payment amount of 3,835 yen per share and a total of 4,555,980 yen. The targeted directors are three members of the Board of Directors. The purpose is to enhance corporate value and motivate management. The transfer restriction period is set at 30 years, a long-term period.\n\n### Purpose of the disposal and future outlook\nThis disposal aims to increase directors' awareness of enhancing corporate value and promote long-term sharing of shareholder value. The disposed shares are managed with transfer restrictions, and they can be transferred under certain conditions or after continuous service. The long-term incentive structure is designed to support sustained corporate growth and shareholder value improvement.","jir_financial_highlights":"Number of shares to be disposed: 1,188 shares (Unknown)\nPayment amount per share: 3,835 yen\/share (Unknown)\nTotal payment amount: 4,555,980 yen (Unknown)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #ShareBuyback, #JapaneseStocks","jir_key_figures":"Number of shares to be disposed: 1,188 shares\nPayment amount: 4,555,980 yen\nPayment amount per share: 3,835 yen","jir_meta_title":"\u3010Towa Pharmaceutical\u3011Share Buyback under Director Compensation System | June 2026","jir_meta_description":"Towa Pharmaceutical announced the disposal of 1,188 shares of treasury stock on June 24, 2026, scheduled for July 10. A key capital policy aimed at long-term incentives.","jir_og_title":"\u3010Towa Pharmaceutical\u3011Share Buyback under Director Compensation System | June 2026","jir_og_description":"Towa Pharmaceutical is disposing of treasury stock to provide long-term incentives for directors. The disposed shares are restricted for 30 years.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-68438","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n